5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study
    Journal Article

    Abida, W.; Campbell, D.; Patnaik, A.; Bryce, A. H.; Shapiro, J.; Bambury, R. M.; Zhang, J.; Burke, J. M.; Castellano, D.; Font, A.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues
    Editorial

    Beije, N.; Abida, W.; Antonarakis, E. S.; Castro, E.; de Wit, R.; Fizazi, K.; Gillessen, S.; Hussain, M.; Mateo, J.; Morris, M. J.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial
    Journal Article

    Chi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Pereira de Santana Gomes, A. J.; Small, E. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma - The authors reply
    Correspondence

    Choueiri, T. K.; Wang, F.; Motzer, R. J.
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial
    Journal Article

    Albiges, L.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Stus, V.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study
    Journal Article

    Pant, S.; Schuler, M.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Minchom, A.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
    Journal Article

    Tvingsholm, S. A.; Frej, M. S.; Rafa, V. M.; Hansen, U. K.; Ormhøj, M.; Tyron, A.; Jensen, A. W. P.; Kadivar, M.; Bentzen, A. K.; Munk, K. K.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: Analysis of the phase 3 randomized CLEAR Study
    Journal Article

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso-Gordoa, T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    European Urology Oncology (2023)

    Fulltext@MSK | Save
  • Immunotherapy combinations for metastatic castration-resistant prostate cancer - Failed trials and future aspects
    Review

    Slovin, S. F.
    Current Opinion in Urology (2023)

    Fulltext@MSK | Save
  • Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
    Journal Article

    Tang, C.; Xie, A. X.; Liu, E. M.; Kuo, F.; Kim, M.; DiNatale, R. G.; Golkaram, M.; Chen, Y. B.; Gupta, S.; Motzer, R. J.; more...
    Cell Metabolism (2023)

    Fulltext@MSK | Save